Thumbnail Image
Publication

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber, J
; 
D'Angelo, S
; 
Minor, D
; 
Hodi, F
; 
Gutzmer, R
; 
Neyns, B
; 
Hoeller, C
; 
Khushalani, N
; 
Miller, W
; 
Lao, C
... show 10 more
Citations
Altmetric:
Abstract
Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, can result in durable responses in patients with melanoma who have progressed after ipilimumab and BRAF inhibitors. We assessed the efficacy and safety of nivolumab compared with investigator's choice of chemotherapy (ICC) as a second-line or later-line treatment in patients with advanced melanoma.
Authors
Weber, J
D'Angelo, S
Minor, D
Hodi, F
Gutzmer, R
Neyns, B
Hoeller, C
Khushalani, N
Miller, W
Lao, C
Linette, G
Thomas, L
Lorigan, Paul C
Grossmann, K
Hassel, J
Maio, M
Sznol, M
Ascierto, P
Mohr, P
Chmielowski, B
Bryce, A
Svane, I
Grob, J
Krackhardt, A
Horak, C
Lambert, A
Yang, A
Larkin, J
Affiliation
Moffitt Cancer Center, Tampa, FL, USA.
Description
Date
2015-04
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Article
Citation
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. 2015, 16 (4):375-84 Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/550190
Embedded videos